Chugai Pharmaceutical Co

Chugai Pharmaceutical Co., a Japan-based Pharmaceutical Preparation Manufacturing company, reported its latest carbon emissions data for 2025. In 2025, the company's Scope 3 emissions were approximately 980,500,000 kg CO2e. For 2024, their Scope 3 emissions were approximately 1,140,500,000 kg CO2e, and in 2023, they were approximately 1,103,800,000 kg CO2e.

For 2022, Chugai Pharmaceutical Co. reported its comprehensive emissions: Scope 1 emissions were approximately 49,400,000 kg CO2e, Scope 2 (market-based) emissions were approximately 11,940,000 kg CO2e, and Scope 3 emissions were approximately 2,232,700,000 kg CO2e.

Chugai Pharmaceutical Co. has committed to several climate targets. The company aims to achieve net-zero emissions for Scope 1 and Scope 2 by 2050.

Science Based Targets initiative (SBTi) commitments for Chugai Pharmaceutical Co., Ltd. include:

• A near-term target to reduce absolute Scope 1 and 2 GHG emissions by 60% by 2030 from a 2019 base year.
• A commitment to increase annual sourcing of renewable electricity from 0% in 2019 to 100% by 2025.
• A near-term target to reduce absolute Scope 3 GHG emissions by 30% by 2030 from a 2019 base year.

The company's SBTi targets for Scope 1 and 2 are consistent with reductions required to keep warming to 1.5°C.